
MK-3207
CAS No. 957118-49-9
MK-3207( MK3207 | MK 3207 )
Catalog No. M16837 CAS No. 957118-49-9
A highly potent, selective CGRP receptor antagonist with Ki of 21 pM in in vitro binding assay and IC50 of 0.12 nM in cell-based functional assay.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
10MG | 323 | In Stock |
![]() ![]() |
100MG | Get Quote | In Stock |
![]() ![]() |
200MG | Get Quote | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameMK-3207
-
NoteResearch use only, not for human use.
-
Brief DescriptionA highly potent, selective CGRP receptor antagonist with Ki of 21 pM in in vitro binding assay and IC50 of 0.12 nM in cell-based functional assay.
-
DescriptionA highly potent, selective CGRP receptor antagonist with Ki of 21 pM in in vitro binding assay and IC50 of 0.12 nM in cell-based functional assay; displays >50000-fold selectivity in a panel of 160 enzymes, receptors, channels, and 65-fold more potent than telcagepant; orally bioavailable.
-
In VitroMK-3207 (0.3, 0.6, 1.1, 2.3, 4.5, 9.0 nM; 30 min) potently blocks human α-CGRP-stimulated cAMP responses in human CGRP receptor-expressing HEK293 cells. Cell Viability Assay Cell Line:HEK293 cells (stably expressing human CLR/RAMP1)Concentration:0.3, 0.6, 1.1, 2.3, 4.5, 9.0 nM Incubation Time:30 min (pre-treat)Result:Blocked human α-CGRP-stimulated cAMP responses with an IC50 value of 0.12 nM.
-
In VivoMK-3207 (0.3, 0.6, 2.1, 9.1, 21.2, 60.6 μg/kg; i.v.; single) inhibits CIDV in rhesus monkeys with EC50 and Emax values of approximately 0.8 nM and 81%.MK-3207 (10 mg/kg; p.o.; single) shows the CSF/plasma ratio is 2 to 3%. Animal Model:Adult rhesus monkeys (4.8-12.7 kg; capsaicin-induced).Dosage:0.3, 0.6, 2.1, 9.1, 21.2, 60.6 μg/kg Administration:Intravenous injection; single.Result:Resulted in an exposure-dependent decrease in capsaicin-induced dermal vasodilation in the rhesus monkey forearm.Animal Model:Adult rhesus monkeys (4.8-12.7 kg).Dosage:10 mg/kg Administration:Oral administration; single.Result:Exhibited the CSF/plasma ratio was 2 to 3%, however the CSF/plasma ratio was approximately 30% of the unbound fraction (9.4%) in plasma.
-
SynonymsMK3207 | MK 3207
-
PathwayGPCR/G Protein
-
TargetCGRP Receptor
-
RecptorCGRP Receptor
-
Research AreaNeurological Disease
-
Indication——
Chemical Information
-
CAS Number957118-49-9
-
Formula Weight557.5905
-
Molecular FormulaC31H29F2N5O3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESC1CCC2(C1)C(=O)N(C(CN2)C3=CC(=CC(=C3)F)F)CC(=O)NC4=CC5=C(CC6(C5)C7=C(NC6=O)N=CC=C7)C=C4
-
Chemical Name6,9-Diazaspiro[4.5]decane-9-acetamide, 8-(3,5-difluorophenyl)-10-oxo-N-[(2R)-1,1',2',3-tetrahydro-2'-oxospiro[2H-indene-2,3'-[3H]pyrrolo[2,3-b]pyridin]-5-yl]-, (8R)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Bell IM, et al. ACS Med Chem Lett. 2010 Jan 12;1(1):24-9.
2. Salvatore CA, et al. J Pharmacol Exp Ther. 2010 Apr;333(1):152-60.
3. Li CC, et al. Br J Clin Pharmacol. 2015 May;79(5):831-7.
molnova catalog



related products
-
Erenumab
Erenumab is a whole-human monoclonal antibody. Erenumab inhibits calcitonin gene-related peptide (CGRP) receptors. Erenumab can be used to prevent migraine attacks.
-
Ubrogepant
Ubrogepant (MK-1602) is a novel potent, selective, oral calcitonin gene-related peptide receptor (CGRP) antagonist for acute treatment of migraine.
-
Calcitonin salmon
Calcitonin salmon, a calcium regulating hormone, is used to treat osteoporosis in women who are at least 5 years past menopause.